A RANDOMIZED, PHASE 3, DOUBLE-BLIND, 52-WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RILZABRUTINIB (SAR444671) COMPARED TO PLACEBO IN ADULT PARTICIPANTS WITH ACTIVE IGG4-RELATED DISEASE

Registry ID

EFC17359

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

SANOFI-AVENTIS CANADA INC

Last update

2025-07-29

Conditions

• IGG4 RELATED DISEASE

Related clinical trials

• A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBEXELIMAB IN PATIENTS WITH IGG4-RELATED DISEASE (INDIGO)
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED STUDY OF INEBILIZUMAB EFFICACY AND SAFETY IN IGG4 RELATED DISEASE

View on source registry